Crossmark

Integrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation

Crossref DOI link: https://doi.org/10.1208/s12248-025-01146-2

Published Online: 2025-10-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Garcia, Luna Prieto https://orcid.org/0000-0003-4625-1190
Nordell, Pär https://orcid.org/0009-0005-7102-9518
Ahlström, Christine https://orcid.org/0009-0003-0575-2295
Lennernäs, Hans https://orcid.org/0000-0002-1578-5184
Sjögren, Erik https://orcid.org/0000-0003-4318-6039
Funding

Funding for this research was provided by:

Uppsala University
License Information

Text and Data Mining valid from 2025-10-06

Version of Record valid from 2025-10-06
More Information

Article History

Received: 11 July 2025

Accepted: 11 September 2025

First Online: 6 October 2025

Declarations

:

: L.P.G., P.N., and A.L. are employees and shareholders of AstraZeneca. The other authors declare no competing interests.

Document is current

Any future updates will be listed below